SLC5A2 and hydrops fetalis: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) constitute one of the four pillars of the medical treatment of heart failure (HF), regardless of ejection fraction and diabetic status, as stressed by the latest update of the 2023 ESC guidelines [1,2,3,4].